ImmunoGen Company Profile (NASDAQ:IMGN)

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Friday, July, 28th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.07. The company earned $39.02 million during the quarter, compared to the consensus estimate of $30.59 million. The company's revenue was up 426.6% on a year-over-year basis. During the same period last year, the firm posted ($0.53) EPS. View ImmunoGen's Earnings History.

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, November, 3rd 2017. View Earnings Estimates for ImmunoGen.

8 equities research analysts have issued 1 year price targets for ImmunoGen's stock. Their predictions range from $1.30 to $12.00. On average, they expect ImmunoGen's stock price to reach $8.05 in the next twelve months. View Analyst Ratings for ImmunoGen.

Here are some recent quotes from research analysts about ImmunoGen stock:

• 1. Cantor Fitzgerald analysts commented, "IMGN’s speed to market strategy with mirvetuximab soravtansine is intended to advance the drug through the regulatory process by the end of 2020 (FORWARD I), and it is on track." (9/25/2017)
• 2. Cowen and Company analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)
• 3. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)

ImmunoGen saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 12,429,992 shares, a decrease of 37.5% from the August 31st total of 19,881,251 shares. Based on an average daily trading volume, of 4,919,562 shares, the days-to-cover ratio is presently 2.5 days. Approximately 14.3% of the shares of the company are sold short.

Some companies that are related to ImmunoGen include Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Esperion Therapeutics (ESPR), Momenta Pharmaceuticals (MNTA), Arena Pharmaceuticals (ARNA), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Albany Molecular Research (AMRI), Abeona Therapeutics (ABEO), Heron Therapeutics (HRTX), Crispr Theraptc (CRSP), ANI Pharmaceuticals (ANIP), AC Immune SA (ACIU), BeyondSpring (BYSI), WAVE Life Sciences (WVE) and Voyager Therapeutics (VYGR).

ImmunoGen's management team includes the folowing people:

• Stephen C. McCluski, Independent Chairman of the Board
• Mark J. Enyedy, President, Chief Executive Officer, Director
• David B. Johnston PhD, Chief Financial Officer, Executive Vice President
• Ellie Harrison, Chief Human Resource Officer, Vice President
• Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
• John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
• Craig Barrows, Vice President, General Counsel, Secretary
• Peter J. Williams, Vice President - Business Development
• Mark A. Goldberg M.D., Independent Director
• Dean Jonathan Mitchell, Independent Director

ImmunoGen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include POLYGON MANAGEMENT LTD. (5.20%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ImmunoGen stock can currently be purchased for approximately $5.86.